These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22930109)

  • 1. [Biologicals for children and adolescents in the treatment of rheumatic diseases].
    Huppertz HI
    Z Rheumatol; 2012 Sep; 71(7):583-9; quiz 590-1. PubMed ID: 22930109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals.
    Beresford MW; Baildam EM
    Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety issues of biologics in pregnant patients with rheumatic diseases.
    Ostensen M
    Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.
    Otten MH; Anink J; Spronk S; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 Nov; 72(11):1806-12. PubMed ID: 23172748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review.
    Lima LM; Aurilio RB; Fonseca AR; Parente AAAI; Sant'Anna MFBP; Sant'Anna CC
    Rev Paul Pediatr; 2023; 42():e2022084. PubMed ID: 37436237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience].
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Reumatismo; 2007; 59(3):244-61. PubMed ID: 17898886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
    Shenoi S; Wallace CA
    Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of biologicals in the treatment of SoJIA].
    Dückers G; Niehues T
    Z Rheumatol; 2010 Aug; 69(6):505-15. PubMed ID: 20668866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study.
    Sozeri B; Ulu K; Kaya-Akça U; Haslak F; Pac-Kisaarslan A; Otar-Yener G; Baba O; Altug-Gucenmez O; Sahin N; Bağlan E; Sönmez HE; Cakmak F; Ozturk K; Gezgin-Yıldırım D; Şener S; Barut K; Batu ED; Yıldız M; Basaran O; Adrovic A; Sahin S; Ozdel S; Bilginer Y; Poyrazoglu MH; Demir F; Yuksel S; Kalyoncu M; Kasapcopur O; Ozen S; Aktay-Ayaz N
    Rheumatol Int; 2022 Mar; 42(3):469-475. PubMed ID: 34570263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on biologicals for treatment of juvenile idiopathic arthritis.
    Horneff G
    Expert Opin Biol Ther; 2013 Mar; 13(3):361-76. PubMed ID: 23289865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biologic therapy of rheumatoid arthritis].
    Damjanov N; Vojinović J
    Srp Arh Celok Lek; 2009; 137(3-4):205-10. PubMed ID: 19459571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].
    Horneff G
    Z Rheumatol; 2005 Jun; 64(5):317-26. PubMed ID: 15965816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.